Price Forecast:

Bullish Case: ACET could rebound as positive clinical trial results for ADI-001 stimulate investor interest, reflected in improved sentiment across social media and high implied volatility in the options market.

Bearish Case: ACET faces significant downside risk from potential trial failures or delays, compounded by negative sentiment and historical price downtrends, making it vulnerable to further declines.

Potential Outcomes:

1. 50% chance: Successful trial results increase shares.

2. 30% chance: Delay or failure leads to significant drops.

3. 10% chance: Regulatory setbacks hinder progress.

4. 10% chance: New partnerships boost outlook.

Trading Oracle: Consider a bullish debit spread on ACET 2.00/5.00 calls for January 2025, targeting a price appreciation of 20% if trial results are positive. This strategy utilizes current high implied volatility for high reward potential with limited downside risk.

December 21, 2024